recently demonstrated an enhancement of metabolic flexibility with transgenic IL-7 production in CAR T cells, with CD4+ IL-7 CAR T cells demonstrating less overall metabolic activity at rest compared to standard CARs but were capable of rapidly downregulating CPT1α upon re-engaging tumor cells, facilitating shifts away from mitochondrial metabolism towards glycolysis and rapid effector reacquisition, leading to superior tumor control (61). This evidence concerns the gene CD4 and neoplasm.